



## Testimonials

GATC Biotech collaborates with world-renowned research institutions and various life science companies. The company has a proven record of publicly funded projects. In the diagnostics sector, one strategic partnership is committed to supporting cancer diagnosis and appropriate treatment decisions to accelerate personalised medicine.

*“ GATC Biotech proved itself to be a reliable sequencing partner in the pilot phase of the project, so we are now continuing that successful collaboration. ”*  
Prof. Dr. Peter Lichter, Head of Molecular Genetics, DKFZ, Heidelberg

*“ GATC Biotech has decades of experience in sequencing technology and services, and a standardised, validated, automated process. Their proven expertise will be invaluable to our team... ”*  
Lloyd Everson, M.D., CEO of MolecularHealth

## Rely on 25 years of expertise and innovation

GATC Biotech has been delivering certified quality for more than 25 years. ISO 17025 accredited production standards and highly automated lab routines ensure consistent analyses and reliable data. Take advantage of our multidisciplinary team consolidated in our Genome and Diagnostics Centre.

**GATC Biotech – we provide solutions to answer scientific questions faster.**



**We can offer you clinical data interpretations including a signed medical report. Please contact us.**

Visit [www.gatc-biotech.com](http://www.gatc-biotech.com) to learn more about GATC Biotech's Diagnostic Solutions, or discover our entire product portfolio for Sanger and whole genome sequencing as well as microbiome, transcriptome and epigenetic studies. For maximum flexibility find out more about **NGSELECT™**, our modular NGS service.



**Contact us:**  
GATC Biotech AG  
European Genome and Diagnostics Centre  
Jakob-Stadler-Platz 7  
78467 Constance  
Germany  
[customerservice@gatc-biotech.com](mailto:customerservice@gatc-biotech.com)  
[www.gatc-biotech.com](http://www.gatc-biotech.com)

## GATC Sequencing Solutions

Extract profound knowledge. Unlock your exome.



## Experience a unique one-stop exome sequencing solution

- Produced under diagnostics standards (ISO 17025)
- Individual batch size starting with one sample
- Fastest service: from sample to result in one week
- Protocol for low-input samples available
- Rapid identification and prioritisation of variants with QIAGEN's Ingenuity® Variant Analysis™
- Guaranteed coverage in multiples of 30x

## Service offerings and quality highlights


### INVIEW HUMAN EXOME

#### Specifications

Starting material	Various sources (tissue, cells, blood and FFPE samples)
Input amount	≥ 100 ng genomic DNA
Sequencing technology	Illumina
Target enrichment	Post-capture indexing format
Sequencing coverage	Guaranteed average on target coverage in multiples of 30x
Delivery time	1 week, 2 or 6 weeks
Deliverables	<ul style="list-style-type: none"> <li>Alignment, SNP and InDel tables including annotated variants and effects</li> <li>Perfectly complemented with QIAGEN's Ingenuity® Variant Analysis™ – a web-based software platform</li> <li>Results summarised in a comprehensive GATC Data Analysis Report</li> </ul>

#### Performance


##### POST-CAPTURE TARGET ENRICHMENT



\*Duplication rate determination not possible due to non-random shearing of DNA

**Fig. 1:** With 70% on-target bases, the latest Agilent post-capture kit performs best with regards to level of mapping rate, detection of SNPs and InDels, and coverage uniformity compared to other target enrichment kits.

##### HIGHER UNIQUE MAPPABILITY RATE



Effect of read length on target coverage of human exome enriched with Agilent's SureSelectXT All Exon V5 capture kit.

**Fig. 2:** The longer read length achieved with the 125 bp read mode improves the mapping efficiency remarkably, by placing reads on the exome more precisely and thus leading to a higher unique mapping rate.

#### Best suited for

- Applications
- Fast detection, analysis and interpretation of data showing relevant genetic variations
  - Translational studies or research on Mendelian disorders and hereditary cancers
  - Clinical research in general

